OXIS International, Inc. (OTCMKTS:OXIS) said that the CEO Tony Cataldo has accepted to attend the Business of Biotech 2015 conference on April 17, 2015 at the Moffitt Cancer Center in Florida. The headline of the 2015 Business of Biotech Conference is “Collaborate to Innovate.” It is the nine conference of Business of Biotech.
OXIS CEO will be discussing the topic of ‘Raising Funds, What is trending now?’ He will highlight the various fundraising strategies and recent trends from evolving life science firms. There will be many other executives from firms like Lion Biotechnologies Inc (NASDAQ:LBIO), MetaStat Inc (OTCMKTS:MTST), Signal Genetics Inc (NASDAQ:SGNL) and Cvergenx to participate on the panel.
Cataldo said that he look forward to participate in the Moffitt Biotech Conference. The company is now well-positioned to take a major step forward with its superior technologies which are at the pioneering edge of immunotherapeutics in the vast cancer therapies markets.
Resumption of trading
In unrelated news, OXIS announced resumption of trading of its common stock on Euronext Paris effective April 14. Upon resumption of trading, OXIS shares will trade in a “double call auction” mode rather than the continuous mode formerly applicable on the company’s shares.
Cataldo said that the management believes the new trading mode will improve efficient trading across the markets on the OTC as well as Euronext. The recent modification in trading form has been approved by the exchange.
OXIS operates in biotech industry and develops and sells innovative drugs made of therapeutic molecules including cannabinoids. The drugs are meant for the treatment of several cancer indications. The company is working to resolve the clinical drawbacks of existing commercial offerings in related fields.
It has developed relationships with leading cannabinoids researchers and pioneer institutions to advance its technologies. In last trading session, the stock price of OXIS declined 7.69% to close at $0.300 on share volume of 8.33 million.